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Alteration of gut microbiota is involved in several chronic inflammatory and
autoimmune diseases, including rheumatoid arthritis, and gut microbial “pro-
arthritogenic” profiles have been hypothesized. Intestinal inflammation may be involved
in spondyloarthropathies and in a subset of patients affected by Juvenile Idiopathic
Arthritis (JIA), the most common chronic rheumatic disease of childhood. We
compared the fecal microbiota composition of JIA patients with healthy subjects
(HS), evaluating differences in microbial profiles between sub-categories of JIA, such
as enthesitis-related arthritis (JIA-ERA), in which inflammation of entheses occurs,
and polyarticular JIA, non-enthesitis related arthritis (JIA-nERA). Through taxon-level
analysis, we discovered alteration of fecal microbiota components that could be involved
in subclinical gut inflammation, and promotion of joint inflammation. We observed
abundance in Ruminococcaceae in both JIA categories, reduction in Clostridiaceae
and Peptostreptococcaceae in JIA-ERA, and increase in Veillonellaceae in JIA-nERA,
respectively, compared with HS. Among the more relevant genera, we found an increase
in Clostridium cluster XIVb, involved in colitis and arthritis, in JIA-ERA patients compared
with HS, and a trend of decrease in Faecalibacterium, known for anti-inflammatory
properties, in JIA-nERA compared with JIA-ERA and HS. Differential abundant taxa
identified JIA patients for the HLA-B27 allele, including Bilophila, Clostridium cluster
XIVb, Oscillibacter, and Parvimonas. Prediction analysis of metabolic functions showed
that JIA-ERA metagenome was differentially enriched in bacterial functions related
to cell motility and chemotaxis, suggesting selection of potential virulence traits. We
also discovered differential microbial profiles and intra-group variability among active
disease and remission, suggesting instability of microbial ecosystem in autoimmune
diseases with respect to healthy status. Similarly to other chronic autoimmune and
inflammatory diseases, different microbial profiles, as observed among different JIA
subgroups compared to HS, and potential functional acquisition related to migration,
could promote inflammation and contribute to the disease pathogenesis.
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INTRODUCTION
Characterization of bacterial commensal communities in
autoimmune and inflammatory diseases is a topic of great
interest for understanding the role and interaction of intestinal
microbiota with the host immune system.
It is known that the gut microbiota is shaped by several
environmental factors, including dietary habits, antibiotics,
infectious agents, and air pollution (De Filippo et al., 2010;
David et al., 2014a; Salim et al., 2014), and in turn, that
microbiota shapes the immune system, modulating homeostasis
in healthy status individuals or promoting inflammation when
dysbiosis occurs. Recent findings demonstrate that alteration in
the equilibrium among commensal bacteria is associated not
only with Inflammatory bowel disease (IBD), allergy, diabetes
and celiac disease (Cheng et al., 2013), but also with rheumatoid
arthritis (Vaahtovuo et al., 2008; Sandhya et al., 2016; Scher et al.,
2016).
Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in children, and comprises a clinically
heterogeneous group of conditions characterized by chronic
arthritis, synovial inflammation and erosion of bone and
cartilage (Ravelli and Martini, 2007). According to several factors,
including the number of affected joints, JIA is divided in psoriatic,
oligoarticular (up to four affected joints), polyarticular (five or
more affected joints) (Oberle et al., 2014), and enthesitis-related
arthritis (ERA), in which entheses (attachments of tendons and
ligaments to bone) are affected. ERA accounts for 10–20% of
JIA and is considered the equivalent of spondyloarthropathy,
a disease frequently characterized by clinical and subclinical
intestinal involvement (Bryan and Rabinovich, 2014; Oberle et al.,
2014; Aggarwal and Misra, 2015).
Immunological, genetic, and environmental factors are
involved in the pathogenesis of ERA (Stoll et al., 2014; Gmuca
and Weiss, 2015). Gene variants in the Major Histocompatibility
Complex, especially the HLA-B27 alleles, have been identified as
predisposing factors (Gmuca and Weiss, 2015).
Alterations of gut microbiota (dysbiosis) and a decrease
in gut microbiota richness (Li et al., 2014; Collado et al.,
2015; Rogers, 2015) are emerging as factors associated with the
development of inflammatory and systemic autoimmune diseases
(Yeoh et al., 2013; Longman and Littman, 2015). Of great interest
is the understanding of dysbiosis as a trigger or a reflection of
autoimmune and inflammatory disorders (Chung and Kasper,
2010; Stoll et al., 2014), in fact, also autoimmunity can drive
instability of the gut microbial ecosystem.
Studies in germ-free animal models reveal relationships
between microorganisms, mucosal immunity, and joint
inflammation (Taurog et al., 1994; Rath et al., 1996; Longman
and Littman, 2015). Recent studies in humans suggest that
alteration of oral and gut microbiota and an increase in leaky
gut could trigger systemic joint inflammation in the context of
pre-existent autoimmunity (Scher et al., 2013, 2015; Brusca et al.,
2014; Costello et al., 2014; Taneja, 2014; Longman and Littman,
2015; Zhang et al., 2015).
However, although arthritis susceptibility has been linked to
the gut microbiome, and it has proposed that in synovial fluids
the presence of pro-arthritogenic bacterial DNA, deriving by
circulating intestinal bacterial products, may promote synovial
inflammation (Kempsell et al., 2000; Gerard et al., 2001; Moen
et al., 2006; Oberle et al., 2014), a causal relationship between
bacterial infection and onset of rheumatological diseases has
not yet been firmly demonstrated. Further studies on leaky
gut syndrome could clarify the presence of bacterial products
circulating and influencing the systemic immune response, also
in light of the presence of bacteria in non-rheumatoid arthritis
controls (Kempsell et al., 2000), and of potential microbial
contamination found in amplification technique of 16S rDNA, as
previous observed (Grahn et al., 2003).
A targeted-metagenomics approach can provide an in-
depth characterization of microbial communities, allowing
investigation of correlations between microbiota composition
and human pathologies (Lozupone et al., 2012).
In this study, we characterized and compared the gut
microbiota of JIA patients, affected by enthesitis-related arthritis
(JIA-ERA) and polyarticular JIA (non-enthesitis-related arthritis,
nERA), with healthy subjects (HS), in order to define specific
microbial “pro-arthritogenic” profiles.
MATERIALS AND METHODS
Sampling of Subjects
We enrolled 29 JIA patients (13 males and 16 females, age
range 2–18 years), 19 of whom were affected by ERA and 10 by
polyarticular JIA (nERA). Exclusion criteria were: acute diarrhea,
infectious gastroenteritis, antibiotic treatment in the previous
3 months, and diagnosis of chronic gastrointestinal disease.
A total of 29 healthy children and adolescents (11 males and 18
females; age range 2–18 years) not affected by autoimmune and
inflammatory conditions, infectious gastroenteritis, or chronic
gastrointestinal disease, were enrolled as controls.
We collected a fecal sample from each subject, and a
second one from 17 ERA patients three months later, in order
to evaluate microbiota variability. We also gathered clinical
information, including: enthesitis and arthritis localization, age
of onset, HLA-B27 status, family history of ankylosing spondylitis
or other HLA-B27-related diseases, comorbidities, laboratory
parameters (C Reactive Protein, Erythrocyte Sedimentation Rate,
ANA and pANCA autoantibody positivity), and pharmacological
treatments (Table 1; Supplementary Tables S1 and S2). None of
the patients underwent treatment with proton pump inhibitors
(PPIs). Active disease was defined by the presence of active
arthritis and/or enthesitis at the time of stool sampling. As
reported in Table 1, a total of four JIA-ERA and four JIA-nERA
patients had clinically active disease. Fecal calprotectin (Aomatsu
et al., 2011) was also assessed by ELISA assay for subclinical
intestinal inflammation (Eurospital, Trieste, Italy). Parents or
guardians gave written informed consent for fecal samples and
clinical data collection of their children. The study protocol
was approved by the Ethics Committee of the Meyer Children’s
Hospital, Florence, Italy (Protocol ref. Nov 12th, 2013), and
carried out in accordance with the approved guidelines.
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TABLE 1 | Clinical features of JIA patients and age/gender information of healthy subjects (HS).
ERA nERA HS
Number 19 10 29
Age (years) median, range 14.3; 9 to 18 10.5; 2 to 17 13; 2 to 18
Male: Female, number 13:6 0:10 11:18
Disease duration (months) median, range 55; 2 to 93 97; 3 to 150 –
Acute disease, number (%) 4 (21%) 4 (40%) –
Calprotectin positive, number (%) 2 (10.5%) 2 (20%) –
High Erythrocyte sedimentation rate, number (%) 3 (15.7%) 0 (0%) –
HLA-B27+ 9 (47%) 0 (0%) –
ANA+ 4 (21%) 9 (90%) –
Complications or comorbidities, number (%)
No 10 (52.6%) 3 (30%) –
Uveitis 1 (5.2%) 7 (70%) –
β- thalassemia 1 (5.2%) 0 (0%) –
Pectum escavatum 2 (10.5%) 0 (0%) –
Asthma 2 (10.5%) 0 (0%) –
Osteoporosis 1 (5.2%) 0 (0%) –
Obesity 1 (5.2%) 0 (0%) –
Hypothyroidism 1 (5.2%) 0 (0%) –
Epigastric hernia 1 (5.2%) 0 (0%) –
Cataract 1 (5.2%) 0 (0%) –
Breast fibroadenoma 1 (5.2%) 0 (0%) –
Treatment, number of patients (%)
NSAIDs 18 (95%) 1 (10%) –
Sulfasalazine 8 (42%) 0 (0%) –
Steroids 4 (21%) 0 (0%) –
Methotrexate 4 (21%) 0 (0%) –
Etanercept 3 (15.7%) 4 (40%) –
Abatacept 1 (5.2%) 5 (50%) –
Adalimumab 2 (10.5%) 0 (0%) –
HLA, Human leukocyte antigen; ANA, Anti-nuclear antibody; NSAIDs, Non-steroidal anti-inflammatory drugs.
DNA Extraction
Fecal samples were preserved in RNAlater (Qiagen) at 4◦C for
the first 48 h, and kept at −80◦C until DNA extraction. Bacterial
genomic DNA extraction and quality control were carried out
following our previous protocol (De Filippo et al., 2010).
Pyrosequencing
For each sample, we amplified the 16S rRNA gene using the
special fusion primer set specific for V5-V6 hypervariable regions
and corresponding to primers 784F and 1061R described by
Andersson et al. (2008), and using the FastStart High Fidelity
PCR system (Roche Life Science, Milano, Italy). The 454
pyrosequencing was carried out on the GS FLX+ system using
the XL+chemistry following the manufacturer recommendations
(details in Supplementary Materials).
Data Analysis
Pyrosequencing resulted in a total of 2,180,826 16S rDNA
reads with a mean of 29,078 sequences per sample. Average
sequence lengths were 290 nt (±SD 45) and 286 nt (±SD 50)
for the first and second run, respectively. Raw 454 files were
demultiplexed using Roche’s.sff file software, and available at
the European Nucleotide Archive1 under the accession study
ERP013262. Reads were pre-processed using the MICCA pipeline
(version 0.1)2 (Albanese et al., 2015). Forward and reverse
primer trimming and quality filtering were performed using
micca-preproc truncating reads shorter than 280nt (quality
threshold = 18). De novo sequence clustering, chimera filtering
and taxonomy assignment were performed by micca-otu-denovo
(parameters -s 0.97 -c). Operational Taxonomic Units (OTUs)
were assigned by clustering the sequences with a threshold of
97% pair-wise identity, and their representative sequences were
classified using the RDP software version 2.7 (Wang et al., 2007).
Template-guided multiple sequence alignment was performed
using PyNAST57 (version 0.1) (Caporaso et al., 2010) against the
multiple alignment of the Greengenes 16S rRNA gene database
(DeSantis et al., 2006) filtered at 97% similarity. Finally, a
phylogenetic tree was inferred using FastTree (Price et al., 2010)
1http://www.ebi.ac.uk/ena/data/view/PRJEB11846
2http://compmetagen.github.io/micca/
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and micca-phylogeny (parameters: -a template-template-min-
perc 50). Sampling heterogeneity was reduced by rarefaction,
obtaining 12,964 sequences per sample.
Chao1 index and Shannon entropy (indicators of alpha
diversity) and UniFrac (Lozupone and Knight, 2005) and Bray–
Curtis dissimilarities (indicators of beta diversity) were calculated
using the phyloseq package (McMurdie and Holmes, 2014) of the
R software suite. Exploratory analysis was performed by Principal
coordinates analysis (PCoA) using the phyloseq package of the
R software suite. Multiple-rarefaction PCoA plots (“jackknifed”
PCoA plots) (Lozupone et al., 2011) were computed to assess the
robustness of the beta-diversity analyses.
The significance of between-groups differentiation on the
UniFrac distances and Bray–Curtis dissimilarity was assessed by
PERMANOVA using the adonis() function of the R package
vegan with 999 permutations.
As a measure of species evenness, we calculated Dominance
(1-Simpson index) and Equitability (Shannon diversity index
divided by the logarithm of taxa number) by using PAST v 3.12
(Hammer et al., 2001).
To compare the relative abundances of OTUs among the three
groups of subjects, the two-sided, unpaired Wilcoxon test was
computed, removing taxa not having a relative abundance of at
least 0.1%, in at least 20% of the samples, and using the function
mt() in the phyloseq library and the p-values were adjusted for
multiple comparison controlling the family wise Type I error rate
(minP procedure). Further significant differences in bacterial taxa
were supported by non-parametric White’s test and Welch’s test
by using STAMP (Parks et al., 2014), and p-values were adjusted
for multiple comparisons by Storey FDR, as proposed in STAMP.
On the basis of the relative abundances, the metagenomic
biomarker discovery and related statistical significance were
assessed using the linear discriminant analysis (LDA) effect size
(LEfSe) method (Segata et al., 2011). LEfSe uses the Kruskal–
Wallis rank-sum test to identify features with significantly
different abundances between assigned taxa compared to the
groups, and LDA to estimate the size effect of each feature. An
alpha significance level of 0.05, either for the factorial Kruskal–
Wallis test among classes or for the pairwise Wilcoxon test
between subclasses, was used. A size-effect threshold of 2.0 on
the logarithmic LDA score was used for discriminative microbial
biomarkers.
In order to predict how taxonomic differences between fecal
microbiota of the three groups impact their microbial metabolic
potential, we applied PICRUSt (Phylogenetic Investigation of
Communities by Reconstruction of Unobserved States) (Langille
et al., 2013), a computational approach useful to infer the
functional contribution of microbial communities on 16S rDNA
sequencing data set. PICRUSt implements an extended ancestral-
state reconstruction algorithm to predict which gene families
are present, and then combines gene families to estimate the
significant differences in the main functional classes (KEGG
categories) of the composite metagenome. From a OTUs table
with associated Greengenes identifiers, we obtained the final
output from metagenome prediction as an annotated table
of predicted gene family counts for each sample, where the
encoded functions of each gene family are orthologous groups or
other identifiers such as KEGG orthologs (KOs). The functional
pathways discovery and related statistical significance were
assessed by LEfSe.
RESULTS
Clinical Features of JIA Patients
We collected clinical features, as well as comorbidities and
therapies, for each enrolled patient at the time of fecal sampling
(Table 1; more details in Supplementary Tables S1 and S2). As
known, due to the two different subsets of JIA, females are
affected from polyarticular JIA two to four times more often
than males (Oberle et al., 2014). In our cohort, most of the
enrolled JIA-ERA patients were males (13/19), while all JIA-
nERA patients were females (10/10). Thus, we evaluated the
sex/gender as a potential variable influencing the fecal microbiota
composition in both JIA categories. Regarding HLA-B27 status,
47% (9/19) of JIA-ERA patients resulted HLA-B27 positive, while
all JIA-nERA patients were HLA-B27 negative. Calprotectin
level, a measurement of intestinal inflammation, was positive
(>100 µg/g) in 10.5% (2/19) of JIA-ERA and in 20% (2/10) of
JIA-nERA patients (see Materials and Methods).
Microbiota Characterization by 16S
rDNA Sequencing in the JIA Groups and
Healthy Controls
We sequenced the V5–V6 hypervariable region of 16S rRNA gene
for the meta-taxonomic study of microbiota in a total of 75 fecal
samples from 19 JIA-ERA patients, 10 JIA-nERA, and 29 HS.
From 17 JIA-ERA patients a second fecal sample was collected
3 months later, to evaluate microbiota variability over time (see
Materials and Methods).
The taxonomic distribution in the three groups showed
variations in gut microbiota composition (Figure 1;
Supplementary Figure S1). Firmicutes, the dominant phylum
of gut microbiota, was the most abundant in all samples (over
50% of total reads; Supplementary Figure S1A). Considering
the 20 most abundant families (Supplementary Figure S1B),
we found statistically significant differences between groups
in Ruminococcaceae, Peptostreptococcaceae, Clostridiaceae I
and Veillonellaceae (Figure 1A). Ruminococcaceae was more
abundant in children in both JIA categories, compared with HS
(21.6% in JIA-ERA and 27.2% in JIA-nERA vs. 12.0% in HS;
Wilcoxon rank-sum test, JIA-ERA vs. HS p = 0.0004; JIA-nERA
vs. HS p = 0.0006; Figure 1A). Although there was a reduction
of Peptostreptococcaceae and Clostridiaceae I in all JIA patients
(ERA and nERA) compared with HS (0.3% in JIA-ERA, 0.4%
in JIA-nERA and 1.1% in HS; 0.1% in JIA vs. 0.5% in HS,
respectively), we found statistically significant differences only
between JIA-ERA vs. HS (Wilcoxon rank-sum test, p = 0.033 for
Peptostreptococcaceae, p= 0.017 for Clostridiaceae I, respectively,
Figure 1A). We observed a statistically significant predominance
of Veillonellaceae in JIA-nERA compared with HS (1.4% in
JIA-nERA vs. 0.4% in HS; Wilcoxon rank-sum test, p = 0.012;
Figure 1A).
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FIGURE 1 | Relative abundances of fecal bacterial components in JIA and HS groups. Box plot of statistically significant different bacterial (A) families and
(B) genera in JIA patients compared to HS (Pairwise comparisons using Wilcoxon rank sum test; ∗∗∗p < 0.001; ∗∗p < 0.01; ∗p < 0.05 FDR adjusted). For
Faecalibacterium genus, statistical significance of the comparison JIA-ERA vs. JIA-nERA was obtained by Welch’s test without multiple testing correction.
Considering gender as potential variable influencing the gut
microbiota composition, we confirmed that among the enrolled
female subjects (6 JIA-ERA, 10 JIA-nERA, and 18 HS), Firmicutes
were more abundant in the JIA-nERA group compared with HS
(Supplementary Figure S2A; Wilcoxon rank-sum test p < 0.05).
Among the minor constituents of fecal microbiota, we observed
an increase in Sutterellaceae and Enterobacteriaceae in JIA-ERA
female patients compared with female HS (2.5% in JIA-ERA vs.
1.2% in HS and 0.5% in JIA-ERA vs. 0.3% in HS, respectively;
Wilcoxon rank-sum test, p < 0.05; Supplementary Figure S2B),
and Streptococcaceae in JIA-nERA compared with HS (1% in
JIA-nERA vs. 0.3% in HS; Wilcoxon rank-sum test, p < 0.05;
Supplementary Figure S2B).
At genus level, we found an abundance of Clostridium cluster
XIVb in JIA-ERA patients compared with HS (0.23% in JIA-ERA
vs. 0.1% in HS; Wilcoxon rank-sum test, p = 0.007; Figure 1B).
Moreover, we observed a decrease in the relative abundance in
Faecalibacterium in JIA-nERA compared with either JIA-ERA
or HS, even if not statistically significant (0.18% in JIA-nERA
vs. 0.35% in HS; 0.18% in JIA-nERA vs. 0.41% in JIA-ERA;
Figure 1B).
By LDA Effect Size (LEfSe; see Materials and Methods), we
evaluated significant differences in abundance between assigned
taxa with respect to JIA patient groups. We observed differentially
abundant taxa discriminating for HLA-B27 status. At family level,
increased Lactobacillaceae in HLA-B27 positive-JIA patients, and
Pasturellaceae in HLA-B27 negative-JIA patients were found
(Figure 2A). Of the increased genera in HLA-B27 positive JIA
patients, we observed Bilophila, Parvimonas, and Oscillibacter,
while Haemophilus and Eggerthella, were differentially enriched
in HLA-B27 negative patients (Figure 2B). When considering
only the JIA-ERA group, in addition to the five genera
reported in Figure 2B, Lactobacillus, Clostridium cluster XI,
and Dialister were enriched in HLA-B27 positive patients, while
only Haemophilus discriminated for HLA-B27 negative status
(Figure 2C).
Further, we evaluated correlations between microbiota profiles
of JIA patients and fecal calprotectin, as well as with respect
to different medical treatments. We did not find any significant
correlation between fecal calprotectin levels and microbiota
profiles (Supplementary Tables S1 and S2), probably due to the
low number of patients with concomitant intestinal inflammation
at the time of sampling. Regarding the effect of pharmacological
therapies on gut microbiota of JIA patients, in our cohorts, JIA-
ERA patients were treated with NSAIDs, alone or associated with
sulfasalazine/methotrexate/biologics in different combinations,
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FIGURE 2 | Differences in bacterial taxa related to HLA-B27 status. LEfSe analysis shows a statistically significant enrichment of (A) families, and (B,C)
genera, in (A,B) all JIA patients and in (C) JIA-ERA patients, considering the HLA-B27 status. LEfSe results indicate a sequentially significant ranking among groups
(Alpha value = 0.05 for the factorial Kruskal–Wallis test among classes). The threshold for the logarithmic LDA score was 2.0.
as reported in Table 1 and Supplementary Table S1. JIA-
nERA patients were mainly treated with biologic drugs, such as
Abatacept and Etanercept (Table 1; Supplementary Table S2).
Despite the low number of patients stratified by pharmacological
treatment, LEfSe analysis showed indications of association
among different bacterial profiles and therapies (as reported
in Supplementary data and Supplementary Figures S3A–C),
among which we observed enrichment in Collinsella, associated
with exacerbation of joint disease (Chen et al., 2016), in JIA-
ERA patients treated with combined NSAIDs and sulfasalazine
therapy.
However, a larger cohort of patients would be needed
to strengthen our preliminary results and to understand the
causality between therapies, gut microbiota profiles and clinical
status.
In order to evaluate differences in the microbial biodiversity
(alpha-diversity) among groups, we calculated the observed
number of OTUs (a measurement of the total number of species
present in a microbial community) and the Chao1 index (an
indicator of species richness based on number of rare species),
observing a significant reduction in alpha diversity in the JIA
samples compared to HS (Figures 3A,B; p-value < 0.005 JIA-
ERA vs. HS and JIA-nERA vs. HS; Supplementary Table S3).
This suggests that microbiota of JIA patients is associated with
biodiversity depletion, as observed in IBD patients. However,
we did not find significant differences among the three groups
using measures of biodiversity that take the evenness of the
species distributions into account, like the Shannon entropy
(Figure 3C), the Dominance (1-Simpson index) and Equitability
(Pielou index; Materials and Methods; Supplementary Figure S4).
To estimate the variability of microbial communities between-
sample (beta-diversity), we calculated the Bray-Curtis and
unweighted UniFrac dissimilarities (see Materials and Methods).
PCoA on unweighted UniFrac dissimilarities showed that
both JIA samples (ERA and nERA) were more similar to
each other than to HS samples (Figure 3D). Bray Curtis
dissimilarity confirmed the differences among samples in the
three populations (PERMANOVA, p < 0.001; Figure 3E).
Considering HLA-B27 status, PCoA, calculated on unweighted
UniFrac and Bray–Curtis dissimilarity, showed that HLA-B27
positive JIA-ERA patients form subgroups with respect to
other JIA-ERA samples (Figures 3F,G), confirmed also by
neighbor joining clustering based on Bray–Curtis dissimilarities
(Supplementary Figure S5). However, the sample distribution of
patients and HS was more marked based on disease and health
status (Figures 3D,E).
Fecal Microbiota Comparison between
Acute Disease and Remission in JIA
Categories
At the moment of fecal sampling, 21% of JIA-ERA patients
(4/19) and 40% of JIA-nERA patients (4/10) had clinically active
disease. Despite the reduced number of samples, LEfSe analysis
showed significant differences in abundances of bacterial genera
in samples collected during clinically active disease and during
remission. In particular, Sutterella was increased in samples
collected during active disease, while Clostridium cluster IV and
XVIII, Parasutterella and Odoribacter were enriched in samples
collected from patients in remission (Figure 4A).
Furthermore, we calculated intra-group distances by
unweighted UniFrac, comparing all JIA samples collected from
patients with active disease and those in remission, versus
the HS samples. Although differences were not statistically
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FIGURE 3 | Alpha and beta diversity measures. (A–C) Box plots of (A) number of observed OTUs, (B) Chao 1, and (C) Shannon indexes in the three studied
populations. Pairwise comparisons using the Wilcoxon rank sum test., ∗∗p-value < 0.005, false discovery rate adjustment. (D,E) PCoA of (D) unweighted UniFrac
and (E) Bray–Curtis dissimilarities. (F,G) PCoA of unweighted UniFrac and Bray–Curtis dissimilarities considering HLAB27 status (red asterisks). Colored dots:
red = JIA-ERA, orange = JIA-nERA, and green = HS samples.
significantly, we observed a trend indicating higher intra-group
distances between JIA-ERA samples collected during active
disease with respect to intra-group distances between JIA-
nERA during active disease (Figure 4B; intra-active JIA-ERA
vs. intra-active JIA-nERA; Supplementary Table S4). Within
the JIA-ERA group, we found more variation in microbiota
profile in samples collected during active disease compared to
remission (Figure 4B; intra-active JIA-ERA vs. intra-remission
JIA-ERA; Supplementary Table S4). On the contrary, although
not statistically significantly different, the intra-distance of
active disease samples in the JIA-nERA group was lower than
in remission samples (Figure 4B; intra-active JIA-nERA vs.
intra-remission JIA-nERA; Supplementary Table S4), indicating
different microbial heterogeneity in active disease and remission
in the two different JIA subsets. Comparing the samples collected
from patients in remission, we observed that distances within
the JIA-nERA group were greater than within the JIA-ERA
group (Figure 4B; intra-remission JIA-nERA vs. intra-remission
JIA-ERA; Supplementary Table S4).
Interestingly, when we compared JIA groups with HS, the
intra-group distance in the HS group was lower than within
both JIA groups (Figure 4B) and significantly correlated with
intra-distances observed in JIA-ERA patients, either active or
in remission, and with intra-distance observed in JIA-nERA
patients in remission (Wilcoxon rank-sum test; intra-HS vs.
intra-active JIA-ERA p = 0.02; intra-HS vs. intra-remission
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FIGURE 4 | Fecal microbiota comparison in patients during acute disease and in remission. (A) LEfSe analysis shows a statistically significant enrichment of
bacterial genera in JIA patients, in active disease (black) and in remission (white). LEfSe results indicate significant ranking among groups (Alpha value = 0.05 for the
factorial Kruskal-Wallis test among classes). The threshold for the logarithmic LDA score was 2.0. (B) Intra-group distances calculated by Unweighted UniFrac
between samples collected during active disease and in remission from JIA-ERA and JIA-nERA patients. P-values displayed are the results of Wilcoxon rank-sum
tests. (C) Box plots of relative distances, calculated by Unweighted UniFrac, among different JIA samples and HS samples and distances of different the two
samples of the same JIA-ERA patient. P-values displayed are the results of Wilcoxon rank sum test; ∗p-value < 0.05, ∗∗p-value < 0.01; ∗∗∗p-value < 0.001.
JIA-ERA p = 0.0004; intra-HS vs. intra-remission JIA-nERA
p= 0.03; Supplementary Table S4), indicating that the microbiota
composition within the healthy group was significantly more
homogeneous than those within the JIA groups.
Next, we evaluated microbiota variations over time in patients
of the JIA-ERA group, considering pairwise UniFrac distances
between samples A and B (collected three months apart; see
Materials and Methods). The matrices obtained by PCoA, derived
from pairwise unweighted and weighted UniFrac distances
between samples A vs. B, allowed us to explore inter- and intra-
individual similarities or dissimilarities among samples, showing
in most part of the cases lower distances between samples of the
same patient than from different patients (Supplementary Figure
S6). Comparing the distributions among all JIA and HS samples
vs. the JIA-ERA samples at two different times by Unweighted
UniFrac mean distances, we confirmed that samples from the
same patient are more similar than samples from different
patients, as well as samples from HS, as expected (Figure 4C).
Metabolic Function Prediction
The microbiota is able to affect host physiology and metabolic
functions, contributing to normal development, and homeostasis
of the immune system in the gut, modulating epithelial cell
proliferation, and protecting against pathogenic bacteria
(Tremaroli and Backhed, 2012; Sommer and Backhed, 2013).
Bacterial species are known to carry and transfer operons
containing genes for different metabolic functions. Different
bacterial species are enriched for certain functions and these
correlations have been categorized in well-organized databases
(Kanehisa et al., 2014). Therefore, in order to clarify how
phylogenetic differences between the fecal microbiota of JIA
patients impact their metabolic potential, we applied PICRUSt
(Phylogenetic Investigation of Communities by Reconstruction
of Unobserved States), a computational approach used to
predict the functional composition of a metagenome (Langille
et al., 2013). LEfSe analysis performed on PICRUSt output
(Supplementary Table S5) showed differentially enriched
functional classes (KEGG categories) among JIA subgroups
compared with HS (Figure 5). Within the main KEGG
categories, we observed significant enrichment of functions
related to cell motility (Flagellar assembly, Ko:02040, Bacterial
chemotaxis and Bacterial motility proteins, Ko:02030) in JIA-
ERA compared with JIA-nERA and HS (Figures 5A,B). Pathways
related to Membrane transport (Secretion system, Ko:03070)
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FIGURE 5 | Metabolic function prediction associated to the microbiota profiles. LEfSe analysis, performed on metabolic functions inferred by PICRUSt
analysis shows statistically significant enrichment of KEGG categories in (A) JIA-ERA vs. JIA-nERA, (B) JIA-ERA vs. HS, and (C) in JIA-nERA vs. HS. LEfSe results
indicate significant ranking among groups (Alpha value = 0.05 for the factorial Kruskal–Wallis test among classes). The threshold for the logarithmic LDA score
was 2.0.
and unclassified Cellular Processes and Signaling (Sporulation)
were significantly enriched, respectively, in JIA-ERA and JIA-
nERA compared with HS group (Figures 5B,C). A remarkable
enrichment in metabolic functions regarding carbohydrate
metabolism, lipid metabolism, aminoacid metabolism, and other
aminoacid metabolism identified a core of metabolic capabilities,
especially in JIA-nERA metagenome compared to JIA-ERA
(Figure 5A) and HS (Figure 5C). On the other hand, metabolism
of cofactors and vitamins (folate biosynthesis and nicotinate and
nicotinamide metabolism) and metabolism of other aminoacids
(Glycine, Serine, Threonine) significantly characterized HS
metagenome compared to JIA-ERA (Figure 5B).
DISCUSSION
There are many lines of evidence that link the microbiota to
rheumatic diseases. Animal models have been used to establish
this possible correlation, such as the use of germ-free and
gnotobiotic mice, in which animals were colonized with a
specific microbial population, or through the use of antibiotics
to understand the effect of microbiota modulation on rheumatic
diseases. Principal limits of animal studies are the sample size and
the difficulty to mimic the complex multifactorial pathogenesis of
these pathologies.
In our study, we tried to define the role of microbiota in
patients affected by JIA. Alterations and decrease of microbiota
richness were recently found in JIA compared with healthy
controls (Stoll et al., 2014), as well as in rheumatoid arthritis,
ankylosing spondylitis and psoriatic arthritis, the latter two
conditions related to spondyloarthropathies (Stebbings et al.,
2002; Scher et al., 2013, 2015; Costello et al., 2014; Gill
et al., 2015). We also observed variations in fecal microbiota
composition and a reduction of microbial richness among JIA
patients, affected by ERA and polyarticular JIA (nERA), in
comparison with HS.
When compared to HS, in both JIA categories, we found
statistically significant abundance in Ruminococcaceae, reduction
in Clostridiaceae and Peptostreptococcaceae in JIA-ERA, and
increase in Veillonellaceae in JIA-nERA. Of note, abundance
in Veillonellaceae was recently found associated to ankylosing
spondylitis (Costello et al., 2014). Conversely to our results,
previous studies on ankylosing spondylitis (Costello et al., 2014;
Scher et al., 2015) and on oligoarticular and polyarticular JIA
(Tejesvi et al., 2016) showed depletion of either Ruminococcaceae
or Veillonellaceae.
The enrichment of anaerobic Gram-positive Clostridium
cluster XIVb in JIA-ERA patients suggests a causal relation with
inflammation. In fact, members of cluster XIVb, C. propionicum,
and C. colinum (Collins et al., 1994) were previously observed
in poultry ulcerative enteritis (Berkhoff, 1985). Also, studies
in animal models have indicated that cell wall peptidoglycans
of Clostridium and other anaerobic Gram-positive species
can induce either chronic and erosive or transient arthritis
(Severijnen et al., 1989; Simelyte et al., 2003). The observed
decreasing trend in Faecalibacterium in JIA-nERA, considered to
be an anti-inflammatory microorganism and a marker of health,
has also been consistently reported in Crohn’s disease patients
(Sokol et al., 2008). Conversely to our results, a recent study
showed reduction of Faecalibacterium prasnutzii in JIA-ERA
patients (Stoll et al., 2014).
The partial agreement of our findings with results obtained
in other studies could be due to several factors, including
variabilities and size of cohorts (different JIA categories, disease
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status, untreated, or treated patients), as well as geography,
environment or dietary habits of the patients, as shown by David
and co-workers (David et al., 2014b).
Despite the limited possibility to generalize our results, due
to the reduced number of patients in the cohorts, our results
on JIA show intriguing links in terms of fecal microbiota
profiles, with IBD and other autoimmune diseases associated to
gastrointestinal disorders.
We are well aware that the known predominance of
females in JIA-nERA introduces a potential gender effect, yet
Enterobacteriaceae and Streptococcaceae, enriched in JIA-ERA
and in JIA-nERA female patients, were also found to be correlated
with intestinal inflammation as observed in biopsy samples of
Crohn’s disease patients (Gevers et al., 2014) and the increase
in Sutterellaceae observed in JIA-ERA female patients, as well
as in samples collected in active disease, is also in line with
increase in Sutterella previously found in children with autism
suffering from gastrointestinal disorder (Williams et al., 2012).
Moreover, in samples collected in remission, we found abundance
in Clostridium spp. cluster IV that have been reported to be
inducers of colonic T regulatory cell (Atarashi et al., 2011), as well
as in Odoribacter, known producer of Short Chain Fatty Acids
(SCFAs), anti-inflammatory metabolites, and previously found
reduced in IBD (Morgan et al., 2012). However, in remission we
also found enriched bacteria involved in intestinal inflammation
and metabolic disorders, such as Parasutterella, found in a
mice model of chemically induced colitis (Zhang et al., 2016),
Clostridium cluster XVIII, encompassing C. ramosum, involved
in diet-induced obesity (Woting et al., 2014) and C. spiroforme,
a toxin-associated disease producer, involved in rabbit colitis
(Carman and Borriello, 1984).
Differentially abundant taxa, previously found in relation
to rheumatoid arthritis, oral infection, intestinal inflammation
or colitis, or to intestinal barrier permeability, discriminate
for positivity of HLA-B27 allele, a genetic marker strongly
associated with spondyloarthropathies. Among these, in HLA-
B27 positive ERA patients we found Bilophila, a sulphite-
reducing bacterium known to be involved in murine colitis
(Devkota et al., 2012) and in intestinal inflammatory disorders
in humans (Loubinoux et al., 2002; Rowan et al., 2009), via H2S
production promoting intestinal inflammation. Parvimonas was
commonly observed in periodontitis and appendicitis (Zhong
et al., 2014), and Oscillibacter was shown to be involved in gut
barrier integrity in mice (Lam et al., 2012). In HLA-B27 negative-
ERA patients, we found Haemophilus and Eggerthella, recently
associated with rheumatoid arthritis (Zhang et al., 2015; Chen
et al., 2016). Moreover, when considering only the ERA group,
in HLA-B27 positive patients we also showed enrichment of
Lactobacillus, observed as potential arthritogenic agent via its cell
wall pepetidoglycan (Severijnen et al., 1989), Clostridium cluster
XI, that includes C. difficile, a well-known proinflammatory and
colitis inducing-bacterium, and Dialister, frequently found in
periodontitis and other infections (Morio et al., 2007).
Recent studies on animal models showed association between
HLA-B27 allele and other different bacterial species, including
B. vulgatus and Prevotella spp. (Lin et al., 2014) and Akkermansia
muciniphila (Asquith et al., 2016). In particular, Akkermansia
spp. was suggested as potential pro-arthritogenic bacterial genus.
However, the study of Stoll and collaborators (Stoll et al., 2014)
showed abundance of Akkermansia in a low percentage of ERA
patients, but no significant association with HLA-B27 status.
In our study, we did not find Akkermansia spp. as part of the
core gut microbiota of our patients, yet we found other species
correlated with HLA-B27 allele. Little is known on the geographic
distribution of Akkermansia spp. that could be less represented
in our cohorts. Overall this could suggest that other bacterial
species, in absence of Akkermansia spp. can discriminate HLA-
B27 status, and that disease biomarkers should be based on
patterns of taxonomic units or biological functions, rather than
on single species.
Regarding the functional contribution of microbiota profiles,
by PICRUSt prediction analysis we observed distinctive
functional acquisitions among JIA subgroups and HS. A core of
metabolic capabilities, regarding carbohydrate, lipid, aminoacid,
cofactors, and vitamins metabolism, were enriched in JIA-nERA
and HS metagenomes. It is worth noting that microbiota of
JIA-ERA patients is significantly enriched in functions related to
cell motility, including flagellar assembly, bacterial chemotaxis
and motility proteins, representing possible traits of virulence
that could be associated to gut inflammation. These indications
of enrichment in potentially pathogenic invasiveness-related
traits in JIA-ERA metagenome could suggest a potential
improved ability of microbial components to pass through
the gastrointestinal barrier and migrate in other districts, also
responding to nutrient gradients. Moreover, given that in mice
models immunogenicity of flagellin CBir1 was observed, with
consequent induction of colitis, and antibodies anti-CBir1 were
found in CD patients with complicated disease (Targan et al.,
2005), we cannot exclude the potential effect of flagellar-assembly
proteins of some components of microbiota on host immune
system of JIA.
Despite the relatively small cohort of patients in our study, the
microbial profile differences in active disease and remission are
corroborated by the observed intra- and inter-group distances
of microbiota samples in active, remission and healthy status.
As expected, our results suggest that during active disease the
microbiota is strongly perturbed (major intra-group distance
compared with remission). Healthy status allows a more stable
microbiota ecosystem compared to disease status, as previously
observed (Coyte et al., 2015). Remission is characterized by an
intermediate microbial pattern, different from both active disease
and healthy controls, likely resulting from a different trajectory
to stable state and in which autoimmune reactivity and the
microbial ecosystem are mutually shaped.
Although microbial profiles may differ in an individual-
specific manner, the observed fecal microbiota dissimilarities
in the same subject at different collection times, and among
JIA categories and healthy controls suggest that continued
perturbation and instability of the microbial ecosystem may
contribute to inflammation.
Another aspect that should be more thoroughly investigated
is the association between microbial profiles and pharmacologic
therapies in autoimmune diseases. Recent studies, as previously
observed in IBD patients, highlighted the effect of different
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therapies on microbiota, such as the rapid effect of enteral
nutrition in the shaping of microbiota (Lionetti et al.,
2005) and the dysbiosis associated with antibiotic treatment
(Lewis et al., 2015), as well as the effect of protonic pomp
inhibitors on reduction of bacterial richness and selection
of “unhealthy” microbiota (Imhann et al., 2016). Moreover,
the recent considerations suggest that the use of sulfasalazine
could protect the intestinal epithelium from injury, reducing
the bacterial product circulation (Rosenbaum and Asquith,
2016). Despite the reduced number of patients on single or
combined therapies in the cohort, our results showed indications
of different microbial profiles associated to pharmacological
therapies, such as NSAIDs, immunosuppressants, and biologics,
providing interesting clues on effect of such treatments on
gut microbiota selection. For example, the enrichment of
Collinsella, involved in exacerbation of joint disease (Chen
et al., 2016), observed in JIA-ERA patients treated with NSAIDs
in combination with sulfasalazine, results in contrast with
hypothesis of Rosenbaum and Asquith (Rosenbaum and Asquith,
2016). Our results prompt future studies on larger cohorts,
including untreated newly onset patients, addressing the effect
of different pharmacological therapies on patients in active
disease and remission, investigating how inflammation can
indirectly modify microbiota, selecting differential microbial
components, via mechanisms involved in epithelial barrier
function and immune response and how pharmacological
treatment contribute to perturb the gut microbial equilibrium
compared to healthy status.
Finally, given the extreme inter-individual variability of
microbiota in inflammatory and autoimmune diseases, further
investigations on microbiota dynamics in different phases
of disease should address the causes of perturbation and
the restoration of microbial equilibrium, in order to adopt
therapeutic strategies able to maintain microbial diversity and
a stable state, essential for immune homeostasis and the host’s
health. Research in this direction should include therapeutic
strategies able to modulate the microbiota, not only with diet
and probiotics, but also evaluating new therapeutic approaches,
such as fecal transplantation, recently adopted in other diseases
and that have shown some effectiveness, especially during
active disease. Furthermore, the understanding of the microbial
functional acquisition and the relationships with epithelial
barrier function and host immune response could help to identify
the pro-arthtritogenic contribution of the microbiota.
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